Table 2.
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Lee et al[92] | 2014 | 10 d | 111 | 1st 5 d: Eso + Amo | 72.1% | 78.4% |
2nd 5 d: Eso + Cla + Met | |||||||
Lee et al[91] | 2015 | 10 d | 100 | 1st 5 d: Rab + Amo | 79.0% | 84.9% | |
2nd 5 d: Rab + Cla + Met | |||||||
China | Zhou et al[93] | 2014 | 10 d | 140 | 1st 5 d: Eso + Amo | 72.1% | 76.5% |
2nd 5 d: Eso + Cla + Tin | |||||||
Qatar | Ben Chaabane et al[94] | 2015 | 14 d | 106 | 1st 7 d: Rab + Amo | 66.0% | 76.0% |
2nd 7 d: Rab + Cla + Met | |||||||
Italy | Pontone et al[187] | 2010 | 10 d | 84 | 1st 5 d: Lan + Amo | 83.3% | 90.9% |
2nd 5 d: Lan + Cla + Met | |||||||
Spain | Molina-Infante et al[114] | 2010 | 10 d | 115 | 1st 5 d: Ome + Amo | 76.5% | 80.8% |
2nd 5 d: Ome + Cla + Met |
ITT: Intention to treat; PP: Per protocol; Lan: Lansoprazole; Amo: Amoxicillin; Cla: Clarithromycin; Met: Metronidazole; Ome: Omeprazole; Eso: Esomeprazole; Tin: Tinidazole; Rab: Rabeprazole.